Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression (PLoS One (2019) 14:2 (e0212254) DOI: 10.1371/journal.pone.0212254)

Academic Article

Abstract

  • © 2019 Maixnerova et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The Supporting Information files were published with tracked changes. Please view the correct files below. Supporting information S1 Table. Baseline characteristics of the 91 Czech patients with biopsy-proven IgA nephropathy. (DOCX) S2 Table. Baseline characteristics of the three groups of the 91 Czech patients with biopsyproven IgA nephropathy (non-progressors, progressors, patients with ESRD). (DOCX) S3 Table. Analysis of a combined group of IgAN non-progressors and progressors vs. IgAN patients who reached ESRD. (DOCX) S4 Table. Median test (Mood test) comparing IgAN patients with end-stage renal disease reached during the follow-up vs. IgAN patients without ESRD for selected variables. (DOCX) S5 Table. Assessment of two groups (non-progressors [n = 70] and progressors [n = 7]) for the influence of E from the Oxford classification (MEST); other parameters (M, S, T) did not reach significance). (DOCX) S6 Table. Influence of Oxford classification MEST composite score in assessment of two groups (non-progressors [n = 70] and progressors [n = 7]). (DOCX) S7 Table. Mean values of selected laboratory parameters in a subset of patients treated with corticosteroids in group 1 with eGFR ?60 mL/min/1.73 m2 (n = 16) and group 2 with eGFR >60 mL/min/1.73 m2 (n = 24). (DOCX) S1 Fig. Discriminant analysis for three groups of IgAN patients (non-progressors in green, progressors in orange, ESRD in blue) and all parameters (eGFR, using MDRD formula (mL/min/1.73 m2); serum IgA (mg/mL); serum Gd-IgA1 (U/1 /g IgA; without neuraminidase); serum Gd-IgA1 (U/mL; without neuraminidase); serum Gd-IgA1 (U/1 /g IgA; with neuraminidase); serum Gd-IgA1 (U/mL; with neuraminidase). (DOCX) S2 Fig. Box-and-whiskers plots for progressors and non-progressors (group 1) vs. IgAN patients who reached ESRD during follow up (group 2) for selected parameters. (DOCX) S3 Fig. Receiver operating characteristic (ROC) curves for non-progressors vs. progressors. a- ROC curve for non-progressors vs. progressors using eGFR (MDRD, mL/min/1.73 m2), Gd-IgA1 biomarkers, and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.936. b- Receiver operating characteristic (ROC) curve for non-progressors vs. progressors using eGFR (MDRD, mL/min/1.73 m2) and Oxford classification (individual parameters of Oxford MEST classification). Area under the curve, AUC = 0.836. (DOCX) S4 Fig. Receiver operator curve within two groups (eGFR, serum levels of IgG autoantibody specific for Gd-IgA1). Area under the curve = 1.00. Accuracy of the discrimination is 100%. Group 1 (n = 35), eGFR 60 mL/min/1.73 m2 at the time of renal-biopsy; group 2 (n = 42), eGFR >60 mL/min/1.73 m2 at the time of renal-biopsy. Prediction equation from logistic regression (predicts probability to choose group 1): Pred(group 1) = 1 / (1 + exp (-(1517.5–1.2E-02?AB-IgA-24.9?eGFR))). (DOCX) S5 Fig. Box-and-whiskers plots for selected variables within two groups. S-creat, serum creatinine (µmol/L); eGFR (MDRD, mL/min/1.73 m2); serum IgG autoantibody specific for Gd- IgA1 (U/mL). Group 1 (n = 35), eGFR ?60 mL/min/1.73 m2 at the time of renal biopsy; group 2 (n = 42), eGFR >60 mL/min/1.73 m2 at the time of renal biopsy. (DOCX).
  • Published In

  • PLoS ONE  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 27318778
  • Author List

  • Maixnerova D; Ling C; Hall S; Reily C; Brown R; Neprasova M; Suchanek M; Honsova E; Zima T; Novak J
  • Volume

  • 14
  • Issue

  • 7